Avacta Group Plc (AVCTF)

Overview

Avacta Group Plc is at the forefront of developing innovative cancer drugs and in vitro diagnostics, with operations spanning the United Kingdom, France, North America, South Korea, the rest of Europe, and other international territories. The company is segmented into two core divisions: Diagnostics and Therapeutics, leveraging its proprietary Affimer and pre|CISION technology platforms. These platforms are pivotal in generating a diverse portfolio of therapeutic and diagnostic products aimed at fulfilling unmet needs across various markets. Since its establishment in 2003, Avacta Group Plc has dedicated itself to transforming patient care through groundbreaking medical research and technology development, headquartered in Wetherby, the United Kingdom.

Products and Services

• AVA6000: A peptide drug conjugate of doxorubicin, currently undergoing Phase I clinical trials. AVA6000 is designed for patients with locally advanced or metastatic solid tumours. Its key differentiator is the utilization of Avacta's pre|CISION technology, which ensures the drug is activated specifically in the tumour, potentially reducing systemic toxicity.
• AVA3996: This therapeutic is a novel tumor-activated proteasome inhibitor based on Velcade. It's in the developmental pipeline, aiming to offer an innovative approach to treating cancer by leveraging the pre|CISION technology for targeted delivery.
• AVA032: A bispecific molecule that is in the pre-clinical trial phase. AVA032 targets the regulation of immune cell activation and proliferation, embodying Avacta's commitment to advancing immunotherapy treatments.
• AVA-028-PD-L1 Affimer/ImmunoCytokines: Currently in development, this product combines Affimer technology with ImmunoCytokines to inhibit PD-L1, a protein that plays a vital role in suppressing the immune response against cancer cells.
• AVA-021 - PD-L1 Affimer/LAG-3 Affimer: Another innovative product leveraging the Affimer technology, aiming to block both PD-L1 and LAG-3 pathways, thus enhancing the immune system's ability to fight cancer.
• TMAC Platform: This transformative platform uses the pre|CISION substrate for the selective release of drug moieties by FAPa, demonstrating Avacta's pioneering approach to developing more targeted and effective cancer therapies.

Furthermore, Avacta has entered a collaboration agreement with LG Chem to expand the development and commercialization of Affimer-based therapeutics, underscoring its strategic partnerships aimed at accelerating product development and maximizing patient impact.